SAN DIEGO, May 18, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) announced today the pricing of
its previously announced underwritten public offering of 10,000,000
shares of its common stock at a public offering price of
$12.50 per share. All of the shares
in the offering are being sold by Halozyme. The gross proceeds from
this offering are expected to be approximately $125 million, before deducting the underwriting
discounts and commissions and estimated offering expenses payable
by Halozyme. The offering is expected to close on May 24, 2017, subject to customary closing
conditions. In addition, Halozyme has granted the underwriters a
30-day option to purchase up to an additional 1,500,000 shares of
common stock at the public offering price, less the underwriting
discounts and commissions, in connection with the offering.
Wells Fargo Securities, LLC and Deutsche Bank Securities are
acting as joint book-running managers for the offering. Barclays
and JMP Securities are acting as co-managers for the offering.
Halozyme intends to use the net proceeds from this offering to
fund continued development of its PEGPH20 oncology program and for
other general corporate purposes.
An automatic shelf registration statement on Form S-3 relating
to the public offering of the shares of common stock described
above was filed with the Securities and Exchange Commission (the
"SEC") and is effective. A preliminary prospectus supplement
relating to the offering has been filed with the SEC and a final
prospectus supplement relating to the offering will be filed with
the SEC. Copies of the final prospectus supplement and accompanying
prospectus may be obtained, when available, from Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, New York 10152,
or by telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com; or Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY 10005, or by telephone at (800)
503-4611 or email to prospectus.cpdg@db.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment.
Safe Harbor Statement
All of the statements in this press release that are not statements
of historical facts constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Examples of such statements include Halozyme's expectations
regarding its fundraising efforts, including the closing of the
public offering, the underwriters' exercise of their option to
purchase additional shares and Halozyme's intended use of proceeds.
These statements are based upon management's current plans and
expectations and are subject to a number of risks and uncertainties
which could cause actual results to differ materially from such
statements. A discussion of the risks and uncertainties that can
affect these statements is set forth in Halozyme's preliminary
prospectus supplement and the accompanying prospectus filed with
the SEC on May 18, 2017, together
with the information incorporated by reference, under the heading
"Risk Factors." Halozyme disclaims any intention or
obligation to revise or update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-prices-public-offering-of-common-stock-300460532.html
SOURCE Halozyme Therapeutics, Inc.